ProShare Advisors LLC Purchases Shares of 25,360 Anavex Life Sciences Corp. (NASDAQ:AVXL)

ProShare Advisors LLC purchased a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXLGet Rating) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 25,360 shares of the biotechnology company’s stock, valued at approximately $440,000.

Other hedge funds have also modified their holdings of the company. Pier Capital LLC acquired a new position in shares of Anavex Life Sciences during the 3rd quarter worth about $4,957,000. Morgan Stanley increased its stake in shares of Anavex Life Sciences by 218.3% during the 2nd quarter. Morgan Stanley now owns 271,673 shares of the biotechnology company’s stock worth $6,211,000 after purchasing an additional 186,329 shares during the last quarter. UBS Group AG increased its stake in shares of Anavex Life Sciences by 2,688.8% during the 3rd quarter. UBS Group AG now owns 179,013 shares of the biotechnology company’s stock worth $3,213,000 after purchasing an additional 172,594 shares during the last quarter. BlackRock Inc. increased its stake in shares of Anavex Life Sciences by 2.8% during the 3rd quarter. BlackRock Inc. now owns 4,433,101 shares of the biotechnology company’s stock worth $79,575,000 after purchasing an additional 120,633 shares during the last quarter. Finally, ACT Capital L.L.C. acquired a new position in shares of Anavex Life Sciences during the 3rd quarter worth about $1,265,000. Hedge funds and other institutional investors own 29.01% of the company’s stock.

NASDAQ AVXL opened at $8.59 on Friday. The company has a market capitalization of $660.72 million, a P/E ratio of -15.07 and a beta of 0.93. Anavex Life Sciences Corp. has a 12-month low of $7.13 and a 12-month high of $31.50. The firm has a 50-day moving average price of $10.77 and a two-hundred day moving average price of $14.23.

Anavex Life Sciences (NASDAQ:AVXLGet Rating) last posted its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. During the same quarter in the prior year, the company posted ($0.12) earnings per share. As a group, research analysts forecast that Anavex Life Sciences Corp. will post -0.91 earnings per share for the current fiscal year.

Several research firms have recently weighed in on AVXL. Zacks Investment Research upgraded shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a research note on Wednesday, March 16th. Finally, StockNews.com assumed coverage on shares of Anavex Life Sciences in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $32.46.

Anavex Life Sciences Company Profile (Get Rating)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.

Further Reading

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.